Our Offerings
Built on 40+ years of scientific innovation, we leverage Quality by Design (QbD) principles and advanced process technologies to develop and manufacture complex APIs, including steroids, peptides, long-chain molecules, and highly potent oncology compounds. Our robust R&D capabilities, strong IP management, and regulatory expertise enable faster development timelines and dependable supply.
Our network of eight global manufacturing facilities operates in compliance with current Good Manufacturing Practices (cGMP) and has been successfully audited by leading regulatory agencies, including the USFDA, EMA, WHO-GMP, PMDA, Health Canada, ANVISA, COFEPRIS, and KFDA.
A resilient supply chain, supported by strategic sourcing partnerships, ensures continuity and reliability. Dedicated teams across quality, regulatory, and commercial functions provide responsive customer support and seamless market access. As a member of the Pharmaceutical Supply Chain Initiative (PSCI), we uphold responsible and sustainable business practices grounded in ethics, human rights, health and safety, environmental stewardship, and strong governance.
Beyond serving generic manufacturers, we also support innovators, CDMOs, and biotechnology companies with specialized technologies, niche manufacturing capabilities, and cost-effective development solutions.
Looking Ahead
Our growth strategy centers on expanding our portfolio of complex and value-added APIs, strengthening peptide capabilities, and deepening partnerships with global pharmaceutical and biotechnology companies. We are also increasing our presence in high-growth markets through new product launches and backward integration into key molecules.
In FY2026, we filed 128 Drug Master Files (DMFs) globally, taking our cumulative filings to 1,748 DMFs worldwide, including 280 active U.S. DMFs as of March 31, 2026. This reflects our continued commitment to building a strong pipeline across key therapeutic areas.
We continue to invest in advanced manufacturing technologies, including Peptides, Continuous manufacturing, HPAPIs, flow chemistry for hazardous and cryogenic reactions, enabling safer operations, improved sustainability metrics, lower operating costs, and greater efficiency. These investments support our broader commitment to manufacturing excellence and environmentally responsible production.
Today, Dr. Reddy’s is a preferred API partner for leading pharmaceutical companies across the U.S., Europe, Latin America, Japan, China, Korea, and emerging markets. By combining scientific innovation, regulatory excellence, cost competitiveness, and exceptional service, we help our partners bring complex therapies to market faster and more efficiently.
